PCN130 Role of the Health Care Payment System on the Patient Access to Oral Anticancer Drugs: A Comparison of French and North American Situations  by Benjamin, L. et al.
the great heterogeneity caused by many treatment arms made it impossible to
develop a feasible model to estimate incremental (cost-) effectiveness compared to
other treatments. CONCLUSIONS: Outcomes research of bortezomib is compli-
cated by extensive treatment variation and great patient heterogeneity in everyday
practice. Although it is possible to generate evidence on appropriate drug use to
facilitate informed decision making, much uncertainty remained regarding the
incremental (cost-) effectiveness compared to other treatments. Policymakers
should carefully consider if outcomes research could potentially lead to an accept-
able reduction in decision-making uncertainty or that other options such as finan-
cial- or outcomes based risk sharing agreements might be more appropriate to
obtain sufficient value for money.
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OBJECTIVES: Targeted therapies are hoped to deliver high-quality, effective treat-
ments that control cost growth. Companion diagnostics (CDs) –biomarker tests to
identify patients likely to benefit– are key to this potential. However, as the US’s
IOM has noted, reimbursement for CDs may not provide optimal incentives to
develop critical CDs. To illustrate, we examined the cost:benefit of CDs based on
current reimbursement levels and the clinical and economic benefit allowed by
biomarker targeting. METHODS: We identified 6 approved CD/therapeutic combi-
nations, all in oncology. Several parameters were obtained: efficacy of therapeutic
in indicated but otherwise un-targeted patients and in patients with the biomarker,
therapeutic and diagnostic costs, and prevalence of the biomarker. CD clinical
benefit was measured by the improvement in therapeutic efficacy in targeted ver-
sus untargeted patients. CD economic benefit was based on therapy cost avoided
assuming that patients in a non-screened scenario undergo 1-month trial. To com-
pare, we estimated a similar measure of the clinical cost:benefit for all oncology
therapies approved since 2000. RESULTS: Estimated net economic benefit of CDs
ranged from about $250 to $8,000. Estimated economic cost: benefit ranged from
approximately $0.05 to $0.55 per USD saved. Estimates of the clinical cost:benefit of
CDs ranged from approximately $1.50 to over $15 per one-percent improvement in
clinical efficacy. Comparison oncology therapies are reimbursed at rates that imply
an average clinical cost:benefit of about $750 per one-percent improvement in
efficacy for non-OS benefits to $2400 per one-percent improvement in OS.
CONCLUSIONS: Our calculations support the IOM statement that current reim-
bursement for CDs may not be optimal. Relative to the value placed on oncology
therapeutics, the reimbursed value CDs is a small fraction of what would be ex-
pected under value-based pricing. This has implications for the structure of the CD
industry as well as the potential for future innovations in diagnostics.
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OBJECTIVES: In various emerging markets coverage of branded drugs is centralized
using a national formulary list of covered products. Among new branded products
pricing and coverage of expensive cancer dugs has been undergoing significant
change in various emerging markets. The objective of this study was to understand
new trends in pricing and coverage of targeted cancer therapies in Russia.
METHODS: To understand the changes in coverage of targeted cancer therapies,
the 2011 and 2012 essential drugs lists for Russia were analyzed for ATC codes
L01XC, L01XE, L01XX, L04AA and L04AX. The newly covered and non-covered prod-
ucts were identified and analyzed for factors driving the change in coverage policy.
For selected analogs price change during 2011 and 2012 was analyzed to under-
stand trends in price set by the government. RESULTS: Analysis of 2011-2012 es-
sential drug lists show significant change in coverage of targeted cancer therapies.
In 2011, only 5 targeted cancer therapies were covered in the essential drug list
(Bevacizumab, Rituximab, Trastuzumab, Imatinib and Bortezomib). In 2012, an
additional 8 branded cancer drugs were added to the list, expanding the coverage of
targeted cancer therapies to 13 products. The price change trend for selected ana-
logs show some products covered at the same price while for others price was
reduced by 5-10%. For example, for one of the covered monoclonal antibodies price
did not change during 2011 and 2012, while prices for a proteasome inhibitor and a
tyrosine kinase inhibitor were lowered by 6% and 10%, respectively.
CONCLUSIONS: Analysis of pricing and coverage of targeted cancer therapies in
Russia shows expansion of access of several products.
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OBJECTIVES: Despite the convenience of oral anticancer drugs (OAD), several fac-
tors restrict the patient access to these treatments including the way the health
care payment system (HPS) reimburses OAD or hospitals services. From the French
and American (U.S) experiences, we aimed at discussing how the HPS may create
disincentives to the use of OAD. METHODS: A literature review was performed
from Medline, Health Insurance reports, law articles, roundtable discussions to
analyze economic challenges of OAD in both systems. RESULTS: French hospitals
are financed by the Health Insurance (HI) according to the nature and quantity of
medical activities. Utilization of OAD shifts medical activities from hospital to
community settings. 2 millions of intravenous (IV) chemotherapy sessions are per-
formed yearly (i.e. 700 million Euros). A 10% decrease of IV chemotherapy sessions
would induce an income loss of 70 million Euros for hospitals. The OAD also gen-
erates additional activities (therapeutic education, control of adherence/side ef-
fects ensuring a safe use) which are not considered in the payment of hospital
activities. Although OAD are fully covered by the HI, physicians may be reluctant to
prescribe OAD partly due to these economic constraints. In the U.S system, the
reimbursement of OAD was limited to those with IV equivalence covered by the
Medicare standard insurance. Since 2003, oral/IV chemotherapy parity legislation
was adopted to provide beneficiaries with an extra-coverage ($2850 covered with a
5% copay) but patients still have to support the cost of drugs before insurance
claims, and may face with heterogeneous co-payments depending on private in-
surances, preventing those with low income to be treated with OAD. A 1% point
reduction in cost-sharing would induce a 2.7% increase in OAD utilization.
CONCLUSIONS: The adaptation of drug reimbursement systems and hospital fi-
nancing are key issues to ensure equal and safe patient access to the most appro-
priate anticancer drugs.
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OBJECTIVES: By utilizing health technology assessments to inform pricing and
reimbursement decisions, payers hope to achieve prices that afford greater value
to health care systems. To determine whether this theory holds true, we aimed to
investigate the link between drug outcomes and pricing in EU5 markets both within
and between therapy areas. METHODS: An initial screen of therapy areas was
conducted to select relevant candidates for further analysis. A qualitative assess-
ment was performed using criteria including: overall budget impact, number of
high cost therapies available, number of new entrants and availability of objective
measure of health outcomes. Based on this screen, oncology and diabetes were
selected for further analysis and comparison. Ten of the most recent entrants were
selected for further analysis in each therapy area. For each product, price premium
relative to the most relevant comparator was calculated in EU5 markets, and com-
pared to incremental change in outcome measures. In oncology, overall survival,
progression free survival and time to progression were selected as outcome mea-
sures. In diabetes, HbA1c reduction, weight loss and proportion achieving HbA1c
target were utilized. RESULTS: As expected, products displaying no or low incre-
mental improvements received minimal price premiums relative to the compara-
tor. However, although improved outcomes were associated with price premiums,
the magnitude of this increase was not correlated to the degree of improvement.
Furthermore, price premiums in oncology varied to a greater extent and reached
higher levels relative to diabetes. CONCLUSIONS: This research indicates that in
EU5 markets, drug pricing has not historically been pegged to health outcomes in a
quantitative manner. With recent and forthcoming evolutions in pricing processes
in Germany and the UK, future approvals in these and other therapy areas may
display more “rational” pricing and deliver greater value to the health care systems.
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OBJECTIVES: The UK National Institute for Health and Clinical Excellence (NICE)
recommended gefitinib for use first line in locally advanced or metastatic, EGFR
mutation positive, NSCLC when supplied via the SPA scheme. This was based on
the mean duration of treatment of 8.8 months observed in the IPASS study. The
single fixed payment under the scheme is triggered at the order of the third pack
and covers a patient for their total supply of gefitinib treatment. The objective of
this study is to evaluate the length of gefitinib therapy and confirm the value
accepted by NICE. METHODS: The SPA administrative database started in Septem-
ber 2009 to collect information on packs (30 days therapy/pack) dispensed to pa-
tients. This retrospective study includes patients fulfilling NICE eligibility criteria
and with at least 12 months potential follow-up and for whom the NHS was in-
voiced. Median time to treatment cessation was estimated from a Kaplan-Meier
curve of packs supplied to patients and mean number of packs dispensed from a
parametric failure time model. RESULTS: 265 patients met the study eligibility
criteria. These patients, for whom the NHS was invoiced the single fixed payment,
received a median of 12 packs 95%CI[10,13] with a mean of 16.2 95%CI[14.1,18.6]
packs per patient. CONCLUSIONS: The results of this observational study indicate
that the average length of gefitinib therapy in UK clinical practice is at least as long
as assumed under SPA which confirms the value accepted by NICE.
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